Date: 2015-04-28
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 10th Drug Discovery Chemistry conference in San Diego, CA.
Company: Oncodesign (France)
Product: RIPK2 drug discovery program
Action
mechanism: kinase inhibitor.
Disease:
Therapeutic area: Autoimmune diseases
Country:
Trial details:
Latest
news: * On April 28, 2015, Oncodesign, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known efficient treatment, has presented new data in support of its RIPK2 drug discovery program at the 10th Drug Discovery Chemistry conference which took place from April 21 to 23 in San Diego, CA. Dr. Jan Hoflack, CSO of Oncodesign, presented in a common track for kinases and macrocyclic drug discovery recent progress made in its RIPK2 program that is based on Oncodesign’s Nanocyclix technology for next generation kinase inhibitors. Nanocyclix gives access to inhibitors for unexplored kinases or for high potential kinases that have remained intractable for more traditional kinase inhibitor approaches up to now. “RIPK2 is a potential therapeutic target for a number of auto-immune diseases. Strong evidence exists that molecules that reduce the activity of this target might be of benefit in Crohn’ disease, asthma, rheumatoid arthritis and multiple sclerosis, as reported by a number of experts in the field,” Dr. Hoflack commented. “We have recently shown the potential value of our compounds in a disease model for Crohn’s disease and IBD (Irritable Bowel Disorders). The effect in this model is through direct interaction with the RIPK2 target and the compounds have also demonstrated excellent propertiesin an ex-vivo model based on human material. These 3 further validations, known in the field as “preclinical Proof-of-Concept”, “Target Engagement” and “Translation to the human situation” are essential arguments in our search for a partner for this exciting program,” Dr. Hoflack added.
